Lv1
63 积分 2021-10-25 加入
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
7天前
已完结
Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment
7天前
已完结
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
7天前
已完结
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure
8天前
已完结
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
8天前
已完结
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
8天前
已完结
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy
1个月前
已完结
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
1个月前
已完结
PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial
3个月前
已完结
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy
3个月前
已完结
皖公网安备34019202002308
